~ Buy the BEVESPI AEROSPHERE (formoterol fumarate; glycopyrrolate) Drug Profile, 2024 PDF Report in the Report Store ~

bevespi aerosphere Drug Patent Profile

✉ Email this page to a colleague

When do Bevespi Aerosphere patents expire, and when can generic versions of Bevespi Aerosphere launch?

Bevespi Aerosphere is a drug marketed by Astrazeneca and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and eighty-seven patent family members in thirty-two countries.

The generic ingredient in BEVESPI AEROSPHERE is formoterol fumarate; glycopyrrolate. There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the formoterol fumarate; glycopyrrolate profile page.

DrugPatentWatch^® Generic Entry Outlook for Bevespi Aerosphere

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 28, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Subscribe

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for bevespi aerosphere?
What are the global sales for bevespi aerosphere?
What is Average Wholesale Price for bevespi aerosphere?

Summary for bevespi aerosphere

International Patents:	187
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2
Drug Prices:	Drug price information for bevespi aerosphere
What excipients (inactive ingredients) are in bevespi aerosphere?	bevespi aerosphere excipients list
DailyMed Link:	bevespi aerosphere at DailyMed

Drug patent expirations by year for bevespi aerosphere

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for bevespi aerosphere

Generic Entry Date for bevespi aerosphere^: ⤷ Subscribe* Constraining patent/regulatory exclusivity: ⤷ Subscribe NDA: 208294 Dosage: AEROSOL, METERED;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for bevespi aerosphere

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bastiaan Driehuys	Phase 2/Phase 3
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	Phase 4
Los Angeles Biomedical Research Institute	Phase 4

See all bevespi aerosphere clinical trials

Pharmacology for bevespi aerosphere

Drug Class	Anticholinergic Cholinergic Muscarinic Antagonist beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists Cholinergic Antagonists Cholinergic Muscarinic Antagonists

US Patents and Regulatory Information for bevespi aerosphere

bevespi aerosphere is protected by seven US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of bevespi aerosphere is ⤷ Subscribe.

This potential generic entry date is based on patent ⤷ Subscribe.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	BEVESPI AEROSPHERE	formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	208294-001	Apr 25, 2016		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Astrazeneca	BEVESPI AEROSPHERE	formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	208294-001	Apr 25, 2016		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Astrazeneca	BEVESPI AEROSPHERE	formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	208294-001	Apr 25, 2016		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for bevespi aerosphere

When does loss-of-exclusivity occur for bevespi aerosphere?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 6621
Patent: COMPOSICIONES PARA EL SUMINISTRO DE ANTAGONISTAS MUSCARINICOS DE ACCION PROLONGADA Y AGONISTA DEL RECEPTOR ADRENERGICO B2 DE ACCION PROLONGADA. METODO DE TRATAMIENTO. SISTEMAS ASOCIADOS. INHALADOR DOSIFICADOR
Estimated Expiration: ⤷ Subscribe

Patent: 6806
Patent: COMPOSICIONES PARA EL SUMINISTRO DE AGENTES ACTIVOS MEDIANTE LAS VIAS RES-PIRATORIAS, Y METODOS Y SISTEMAS ASOCIADOS, COSUSPENSION, INHALADOR DOSIFI-CADOR
Estimated Expiration: ⤷ Subscribe

Patent: 6807
Patent: COMPOSICIONES METODOS Y SISTEMAS PARA EL SUMINISTRO DE DOS O MAS AGENTES ACTIVOS MEDIANTE LAS VIAS RESPIRATORIAS. METODO DE PREPARACION COMPOSICION
Estimated Expiration: ⤷ Subscribe

Patent: 1758
Patent: COMPOSICIÓN FARMACÉUTICA QUE PUEDE SUMINISTRARSE DESDE UN INHALADOR DOSIFICADOR
Estimated Expiration: ⤷ Subscribe

Patent: 2477
Patent: COMPOSICIONES PARA EL SUMINISTRO DE AGENTES ACTIVOS MEDIANTE LAS VÍAS RESPIRATORIAS, Y MÉTODOS Y SISTEMAS ASOCIADOS
Estimated Expiration: ⤷ Subscribe

Patent: 2478
Patent: COMPOSICIONES PARA EL SUMINISTRO PULMONAR DE ANTAGONISTAS MUSCARÍNICOS DE ACCIÓN PROLONGADA Y AGONISTAS DEL RECEPTOR ADRENÉRGICO b₂ DE ACCIÓN PROLONGADA, Y MÉTODOS Y SISTEMAS ASOCIADOS
Estimated Expiration: ⤷ Subscribe

Australia

Patent: 10253770
Patent: Compositions for respiratory delivery of active agents and associated methods and systems
Estimated Expiration: ⤷ Subscribe

Patent: 10253776
Patent: Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting B2 adrenergic receptor agonists and associated methods and systems
Estimated Expiration: ⤷ Subscribe

Patent: 10253950
Patent: Respiratory delivery of active agents
Estimated Expiration: ⤷ Subscribe

Patent: 15201037
Patent: Respiratory delivery of active agents
Estimated Expiration: ⤷ Subscribe

Patent: 17201709
Patent: Compositions, methods & systems for respiratory delivery of two or more active agents
Estimated Expiration: ⤷ Subscribe

Patent: 18282272
Patent: COMPOSITIONS, METHODS & SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS
Estimated Expiration: ⤷ Subscribe

Patent: 20210160
Patent: COMPOSITIONS, METHODS & SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS
Estimated Expiration: ⤷ Subscribe

Brazil

Patent: 1011220
Patent: composição farmacêutica, métodos para tratar uma doença ou distúrbio, para administração respiratória de dois ou mais agentes ativos, para administração respiratória de uma combinação de agentes ativos, e, para preparar uma composição adequada.
Estimated Expiration: ⤷ Subscribe

Patent: 1011229
Patent: co-suspensão, inalador de dose medida, e, métodos de preparação de um inalador de dose medida, de dispensação respiratória de um agente ativo a um paciente, e para tratar de um paciente.
Estimated Expiration: ⤷ Subscribe

Patent: 1011508
Patent: composição farmacêutica, métodos para tratar uma doença ou distúrbio pulmonar em um paciente ou população de pacientes, e para dispensação respiratória de um agente ativo a um paciente, e, inalador de dose medida.
Estimated Expiration: ⤷ Subscribe

Canada

Patent: 63936
Patent: COMPOSITIONS PERMETTANT L'ADMINISTRATION DE PRINCIPES ACTIFS PAR VOIE RESPIRATOIRE ET METHODES ET SYSTEMES ASSOCIES (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 63939
Patent: COMPOSITIONS PERMETTANT L'ADMINISTRATION PAR VOIE PULMONAIRE D'ANTAGONISTES, A ACTION PROLONGEE, DES RECEPTEURS MUSCARINIQUES ET D'AGONISTES, A ACTION PROLONGEE, DES RECEPTEURS ADRENERGIQUES B2 ET METHODES ET SYSTEMES ASSOCIES (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING B2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 63941
Patent: COMPOSITIONS, METHODES ET SYSTEMES PERMETTANT UNE ADMINISTRATION PAR VOIE RESPIRATOIRE DE DEUX PRINCIPES ACTIFS OU PLUS (COMPOSITIONS, METHODS & SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS)
Estimated Expiration: ⤷ Subscribe

China

Patent: 2458364
Patent: Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
Estimated Expiration: ⤷ Subscribe

Patent: 2596176
Patent: Compositions for respiratory delivery of active agents and associated methods and systems
Estimated Expiration: ⤷ Subscribe

Patent: 2753152
Patent: Compositions, methods & systems for respiratory delivery of two or more active agents
Estimated Expiration: ⤷ Subscribe

Patent: 5193773
Patent: Respiratory delivery of active agents
Estimated Expiration: ⤷ Subscribe

Patent: 7412212
Patent: 经肺递送长效毒蕈碱拮抗剂及长效β₂肾上腺素能受体激动剂的组合物及相关方法与系统 (Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta2 adrenergic receptor agonists and associated methods and systems)
Estimated Expiration: ⤷ Subscribe

Patent: 7669664
Patent: 经呼吸递送活性剂的组合物及相关方法和系统 (Compositions For Respiratory Delivery Of Active Agents And Associated Methods And Systems)
Estimated Expiration: ⤷ Subscribe

Croatia

Patent: 0161098
Estimated Expiration: ⤷ Subscribe

Patent: 0161101
Estimated Expiration: ⤷ Subscribe

Patent: 0161102
Estimated Expiration: ⤷ Subscribe

Patent: 0200166
Estimated Expiration: ⤷ Subscribe

Patent: 0200260
Estimated Expiration: ⤷ Subscribe

Patent: 0200298
Estimated Expiration: ⤷ Subscribe

Cyprus

Patent: 18030
Estimated Expiration: ⤷ Subscribe

Patent: 18034
Estimated Expiration: ⤷ Subscribe

Patent: 18040
Estimated Expiration: ⤷ Subscribe

Patent: 22732
Estimated Expiration: ⤷ Subscribe

Patent: 22749
Estimated Expiration: ⤷ Subscribe

Patent: 22807
Estimated Expiration: ⤷ Subscribe

Patent: 19031
Estimated Expiration: ⤷ Subscribe

Denmark

Patent: 35023
Estimated Expiration: ⤷ Subscribe

Patent: 35024
Estimated Expiration: ⤷ Subscribe

Patent: 35025
Estimated Expiration: ⤷ Subscribe

Patent: 06149
Estimated Expiration: ⤷ Subscribe

Patent: 11926
Estimated Expiration: ⤷ Subscribe

Patent: 11927
Estimated Expiration: ⤷ Subscribe

European Patent Office

Patent: 35023
Patent: COMPOSITIONS PERMETTANT L'ADMINISTRATION PAR VOIE PULMONAIRE D'ANTAGONISTES, À ACTION PROLONGÉE, DES RÉCEPTEURS MUSCARINIQUES ET D'AGONISTES, À ACTION PROLONGÉE, DES RÉCEPTEURS ADRÉNERGIQUES 2 ET MÉTHODES ET SYSTÈMES ASSOCIÉS (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING BETA 2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 35024
Patent: COMPOSITIONS PERMETTANT L'ADMINISTRATION DE PRINCIPES ACTIFS PAR VOIE RESPIRATOIRE ET MÉTHODES ET SYSTÈMES ASSOCIÉS (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 35025
Patent: ADMINISTRATION PAR VOIE RESPIRATOIRE DE PRINCIPES ACTIFS (RESPIRATORY DELIVERY OF ACTIVE AGENTS)
Estimated Expiration: ⤷ Subscribe

Patent: 06149
Patent: COMPOSITIONS POUR L'ADMINISTRATION PAR VOIE PULMONAIRE D'ANTAGONISTES MUSCARINIQUES ET AGONISTES DU RÉCEPTEUR ADRÉNERGIQUE BÉTA-2 À ACTION PROLONGÉE, PROCÉDÉS ET SYSTÈMES ASSOCIÉS (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING BETA-2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 11926
Patent: COMPOSITIONS, PROCÉDÉS ET SYSTÈMES POUR UNE ADMINISTRATION RESPIRATOIRE DE DEUX OU DE PLUSIEURS AGENTS ACTIFS (COMPOSITIONS, METHODS & SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS)
Estimated Expiration: ⤷ Subscribe

Patent: 11927
Patent: COMPOSITIONS POUR ADMINISTRATION RESPIRATOIRE D'AGENTS ACTIFS ET MÉTHODES ET SYSTÈMES ASSOCIÉS (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Hong Kong

Patent: 69026
Patent: 用於經由肺部遞送長效蕈毒鹼拮抗劑及長效β 腎上腺素受體激動劑之組成物，及相關方法及系統 (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING BETA ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 69027
Patent: 用於經由呼吸道輸送活性劑的組成物以及相關方法與系統 (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 69307
Patent: 經由呼吸道遞送活性藥劑 (RESPIRATORY DELIVERY OF ACTIVE AGENTS)
Estimated Expiration: ⤷ Subscribe

Patent: 18867
Patent: 活性劑的呼吸遞送 (RESPIRATORY DELIVERY OF ACTIVE AGENTS)
Estimated Expiration: ⤷ Subscribe

Patent: 44669
Patent: 經肺遞送長效毒蕈堿拮抗劑及長效β2腎上腺素能受體激動劑的組合物及相關方法與系統 (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING β2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 47095
Patent: 經呼吸遞送活性劑的組合物及相關方法和系統 (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Hungary

Patent: 29532
Estimated Expiration: ⤷ Subscribe

Patent: 31229
Estimated Expiration: ⤷ Subscribe

Patent: 31283
Estimated Expiration: ⤷ Subscribe

Patent: 47803
Estimated Expiration: ⤷ Subscribe

Patent: 47823
Estimated Expiration: ⤷ Subscribe

Patent: 47834
Estimated Expiration: ⤷ Subscribe

Patent: 900031
Estimated Expiration: ⤷ Subscribe

Patent: 100018
Estimated Expiration: ⤷ Subscribe

Israel

Patent: 6466
Patent: תכשירים לנתינה למערכת הנשימה של גורמים פעילים ושיטות ומערכות קשורות (Compositions for respiratory delivery of active agents and associated methods and systems)
Estimated Expiration: ⤷ Subscribe

Patent: 6467
Patent: תרכובות פרמצבטיות למתן באמצעות משאף מינוני המכילות גליקופירולט או פורמוטרול ושמושן לטיפול במחלות נשימתיות (Pharmaceutical compositions deliverable from a metered dose inhaler comprising glycopyrrolate or formoterol and their use in treatment of pulmonary diseases)
Estimated Expiration: ⤷ Subscribe

Patent: 6468
Patent: תרכובות פרמצבטיות למתן באמצעות משאף מינוני המכילות גליקופירולט ופורמוטרול ושמושן לטיפול במחלות נשימתיות (Pharmaceutical compositions deliverable from a metered dose inhaler comprising glycopyrrolate and formoterol and their use in treatment of pulmonary diseases)
Estimated Expiration: ⤷ Subscribe

Japan

Patent: 23383
Estimated Expiration: ⤷ Subscribe

Patent: 73012
Estimated Expiration: ⤷ Subscribe

Patent: 73013
Estimated Expiration: ⤷ Subscribe

Patent: 69639
Estimated Expiration: ⤷ Subscribe

Patent: 89356
Estimated Expiration: ⤷ Subscribe

Patent: 48645
Estimated Expiration: ⤷ Subscribe

Patent: 92124
Estimated Expiration: ⤷ Subscribe

Patent: 76734
Estimated Expiration: ⤷ Subscribe

Patent: 12528199
Estimated Expiration: ⤷ Subscribe

Patent: 12528200
Estimated Expiration: ⤷ Subscribe

Patent: 12528792
Estimated Expiration: ⤷ Subscribe

Patent: 15187108
Patent: 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 15199735
Patent: ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 (COMPOSITION, METHOD AND SYSTEM FOR DELIVERING TWO OR MORE ACTIVATORS TO RESPIRATORY ORGAN)
Estimated Expiration: ⤷ Subscribe

Patent: 16041713
Patent: 長時間作用性のムスカリン拮抗剤および長時間作用性のΒ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING BETA2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 17222706
Patent: ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 (COMPOSITIONS, METHODS AND SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS)
Estimated Expiration: ⤷ Subscribe

Patent: 18008942
Patent: 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 (COMPOSITION FOR RESPIRATORY DELIVERY OF ACTIVE AGENT, AND RELATED METHOD AND SYSTEM)
Estimated Expiration: ⤷ Subscribe

Patent: 18048150
Patent: 長時間作用性のムスカリン拮抗剤および長時間作用性のΒ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING B2 ADRENERGIC RECEPTOR AGONISTS, AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 19108369
Patent: 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Lithuania

Patent: 435024
Estimated Expiration: ⤷ Subscribe

Patent: 435025
Estimated Expiration: ⤷ Subscribe

Patent: 2019014
Estimated Expiration: ⤷ Subscribe

Patent: 2021511
Estimated Expiration: ⤷ Subscribe

Patent: 35023
Estimated Expiration: ⤷ Subscribe

Patent: 35024
Estimated Expiration: ⤷ Subscribe

Patent: 35025
Estimated Expiration: ⤷ Subscribe

Patent: 06149
Estimated Expiration: ⤷ Subscribe

Patent: 11926
Estimated Expiration: ⤷ Subscribe

Patent: 11927
Estimated Expiration: ⤷ Subscribe

Luxembourg

Patent: 0124
Estimated Expiration: ⤷ Subscribe

Patent: 0208
Estimated Expiration: ⤷ Subscribe

Mexico

Patent: 7126
Patent: ADMINISTRACION RESPIRATORIA DE AGENTES ACTIVOS. (RESPIRATORY DELIVERY OF ACTIVE AGENTS.)
Estimated Expiration: ⤷ Subscribe

Patent: 0163
Patent: COMPOSICIONES PARA SUMINISTRO RESPIRATORIO DE AGENTES ACTIVOS Y METODOS Y SISTEMAS ASOCIADOS. (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS.)
Estimated Expiration: ⤷ Subscribe

Patent: 0164
Patent: COMPOSICIONES PARA SUMINISTRO PULMONAR DE ANTAGONISTAS MUSCARÍNICOS DE ACCIÓN PROLONGADA Y AGONISTAS DE RECEPTOR B2 ADRENÉRGICO DE ACCIÓN PROLONGADA Y MÉTODOS Y SISTEMAS ASOCIADOS. (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING B2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS.)
Estimated Expiration: ⤷ Subscribe

Patent: 11012684
Patent: COMPOSICIONES PARA SUMINISTRO RESPIRATORIO DE AGENTES ACTIVOS Y METODOS Y SISTEMAS ASOCIADOS. (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS.)
Estimated Expiration: ⤷ Subscribe

Patent: 11012685
Patent: COMPOSICIONES PARA SUMINISTRO PULMONAR DE ANTAGONISTAS MUSCARINICOS DE ACCION PROLONGADA Y AGONISTAS DE RECEPTOR B2 ADRENERGICO DE ACCION PROLONGADA Y METODOS Y SISTEMAS ASOCIADOS. (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING B2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS.)
Estimated Expiration: ⤷ Subscribe

Patent: 11012783
Patent: ADMINISTRACION RESPIRATORIA DE AGENTES ACTIVOS. (RESPIRATORY DELIVERY OF ACTIVE AGENTS.)
Estimated Expiration: ⤷ Subscribe

Patent: 20004077
Patent: COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE LA COMBINACIÓN DE ALBUTEROL Y BUDESÓNIDA, ADAPTADA PARA EL SUMINISTRO RESPIRATORIO MEDIANTE UN INHALADOR DE DOSIS MEDIDA Y EL USO DE LAS MISMAS PARA EL TRATAMIENTO DE TRASTORNOS PULMONARES. (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS.)
Estimated Expiration: ⤷ Subscribe

Montenegro

Patent: 631
Patent: SASTAVI ZA ISPORUKU AKTIVNIH AGENASA U DISAJNE PUTEVE I POVEZANI POSTUPCI I SISTEMI (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Netherlands

Patent: 0995
Estimated Expiration: ⤷ Subscribe

Norway

Patent: 19026
Estimated Expiration: ⤷ Subscribe

Patent: 21019
Estimated Expiration: ⤷ Subscribe

Philippines

Patent: 017500778
Patent: COMPOSITIONS, METHODS and SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS
Estimated Expiration: ⤷ Subscribe

Poland

Patent: 35023
Estimated Expiration: ⤷ Subscribe

Patent: 35024
Estimated Expiration: ⤷ Subscribe

Patent: 35025
Estimated Expiration: ⤷ Subscribe

Patent: 06149
Estimated Expiration: ⤷ Subscribe

Patent: 11926
Estimated Expiration: ⤷ Subscribe

Patent: 11927
Estimated Expiration: ⤷ Subscribe

Portugal

Patent: 35023
Estimated Expiration: ⤷ Subscribe

Patent: 35024
Estimated Expiration: ⤷ Subscribe

Patent: 35025
Estimated Expiration: ⤷ Subscribe

Patent: 06149
Estimated Expiration: ⤷ Subscribe

Patent: 11926
Estimated Expiration: ⤷ Subscribe

Patent: 11927
Estimated Expiration: ⤷ Subscribe

Russian Federation

Patent: 80315
Patent: КОМПОЗИЦИИ ДЛЯ РЕСПИРАТОРНОЙ ДОСТАВКИ АКТИВНЫХ ВЕЩЕСТВ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE SUBSTANCES AND METHODS AND SYSTEMS CONNECTED THEREWITH)
Estimated Expiration: ⤷ Subscribe

Patent: 86297
Patent: КОМПОЗИЦИИ, СПОСОБЫ И СИСТЕМЫ ДЛЯ РЕСПИРАТОРНОЙ ДОСТАВКИ ДВУХ ИЛИ БОЛЕЕ АКТИВНЫХ АГЕНТОВ (COMPOSITIONS, METHODS AND SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS)
Estimated Expiration: ⤷ Subscribe

Patent: 13404
Patent: КОМПОЗИЦИИ ДЛЯ ЛЕГОЧНОЙ ДОСТАВКИ АНТАГОНИСТОВ МУСКАРИНОВЫХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И АГОНИСТОВ В2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC RECEPTOR ANTAGONISTS AND LONG-ACTING B2-ADRENERGIC RECEPTOR AGONISTS AND METHODS AND SYSTEMS ASSOCIATED THEREWITH)
Estimated Expiration: ⤷ Subscribe

Patent: 51771
Patent: КОМПОЗИЦИИ ДЛЯ РЕСПИРАТОРНОЙ ДОСТАВКИ АКТИВНЫХ ВЕЩЕСТВ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE SUBSTANCES AND METHODS AND SYSTEMS ASSOCIATED THEREWITH)
Estimated Expiration: ⤷ Subscribe

Patent: 11152960
Patent: КОМПОЗИЦИИ ДЛЯ ЛЕГОЧНОЙ ДОСТАВКИ АНТАГОНИСТОВ МУСКАРИНОВЫХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И АГОНИСТОВ β-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ
Estimated Expiration: ⤷ Subscribe

Patent: 11154083
Patent: КОМПОЗИЦИИ ДЛЯ РЕСПИРАТОРНОЙ ДОСТАВКИ АКТИВНЫХ ВЕЩЕСТВ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ
Estimated Expiration: ⤷ Subscribe

Patent: 11154148
Patent: КОМПОЗИЦИИ, СПОСОБЫ И СИСТЕМЫ ДЛЯ РЕСПИРАТОРНОЙ ДОСТАВКИ ДВУХ ИЛИ БОЛЕЕ АКТИВНЫХ АГЕНТОВ
Estimated Expiration: ⤷ Subscribe

Patent: 15151358
Patent: КОМПОЗИЦИИ ДЛЯ ЛЕГОЧНОЙ ДОСТАВКИ АНТАГОНИСТОВ МУСКАРИНОВЫХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И АГОНИСТОВ В2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ
Estimated Expiration: ⤷ Subscribe

Patent: 16107464
Patent: КОМПОЗИЦИИ ДЛЯ РЕСПИРАТОРНОЙ ДОСТАВКИ АКТИВНЫХ ВЕЩЕСТВ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ
Estimated Expiration: ⤷ Subscribe

Patent: 16117972
Patent: КОМПОЗИЦИИ, СПОСОБЫ И СИСТЕМЫ ДЛЯ РЕСПИРАТОРНОЙ ДОСТАВКИ ДВУХ ИЛИ БОЛЕЕ АКТИВНЫХ АГЕНТОВ
Estimated Expiration: ⤷ Subscribe

Patent: 20102859
Patent: КОМПОЗИЦИИ ДЛЯ ЛЕГОЧНОЙ ДОСТАВКИ АНТАГОНИСТОВ МУСКАРИНОВЫХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И АГОНИСТОВ B2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И СИСТЕМЫ
Estimated Expiration: ⤷ Subscribe

San Marino

Patent: 01600326
Patent: DISTRIBUZIONE RESPIRATORIA DI PRINCIPI ATTIVI
Estimated Expiration: ⤷ Subscribe

Patent: 01600327
Patent: COMPOSIZIONI PER IL RILASCIO POLMONARE DI ANTAGONISTI MUSCARINICI AD AZIONE PROLUNGATA E DI AGONISTI DEL RECETTORE ADRENERGICO BETA 2 AD AZIONE PROLUNGATA E METODI E SISTEMI ASSOCIATI
Estimated Expiration: ⤷ Subscribe

Patent: 01600329
Patent: COMPOSIZIONI PER LA DISTRIBUZIONE RESPIRATORIA DI PRINCIPI ATTIVI E METODI E SISTEMI ASSOCIATI
Estimated Expiration: ⤷ Subscribe

Slovenia

Patent: 35023
Estimated Expiration: ⤷ Subscribe

Patent: 35024
Estimated Expiration: ⤷ Subscribe

Patent: 35025
Estimated Expiration: ⤷ Subscribe

Patent: 06149
Estimated Expiration: ⤷ Subscribe

Patent: 11926
Estimated Expiration: ⤷ Subscribe

Patent: 11927
Estimated Expiration: ⤷ Subscribe

South Africa

Patent: 1108275
Patent: RESPIRATORY DELIVERY OF ACTIVE AGENTS
Estimated Expiration: ⤷ Subscribe

Patent: 1208100
Patent: COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS
Estimated Expiration: ⤷ Subscribe

Patent: 1208101
Patent: COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING B2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS
Estimated Expiration: ⤷ Subscribe

Patent: 1208102
Patent: RESPIRATORY DELIVERY OF ACTIVE AGENTS
Estimated Expiration: ⤷ Subscribe

South Korea

Patent: 1748892
Estimated Expiration: ⤷ Subscribe

Patent: 1926060
Estimated Expiration: ⤷ Subscribe

Patent: 1976107
Estimated Expiration: ⤷ Subscribe

Patent: 120015334
Patent: COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS
Estimated Expiration: ⤷ Subscribe

Patent: 120026075
Patent: RESPIRATORY DELIVERY OF ACTIVE AGENTS
Estimated Expiration: ⤷ Subscribe

Patent: 120034631
Patent: COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING B2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS
Estimated Expiration: ⤷ Subscribe

Patent: 170070274
Patent: 지속형 무스카린 안타고니스트 및 지속형 Ｂ₂아드레날린 수용체 아고니스트의 폐 전달용 조성물, 및 연관된 방법 및 시스템 (COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING B2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 170104003
Patent: 활성제의 호흡기 전달용 조성물, 및 연관된 방법 및 시스템 (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 180130602
Patent: 활성제의 호흡기 전달용 조성물, 및 연관된 방법 및 시스템 (COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS)
Estimated Expiration: ⤷ Subscribe

Patent: 190049943
Patent: 활성제의 호흡기 전달 (RESPIRATORY DELIVERY OF ACTIVE AGENTS)
Estimated Expiration: ⤷ Subscribe

Spain

Patent: 89135
Estimated Expiration: ⤷ Subscribe

Patent: 92536
Estimated Expiration: ⤷ Subscribe

Patent: 93429
Estimated Expiration: ⤷ Subscribe

Patent: 72253
Estimated Expiration: ⤷ Subscribe

Patent: 74367
Estimated Expiration: ⤷ Subscribe

Patent: 74391
Estimated Expiration: ⤷ Subscribe

Taiwan

Patent: 39979
Estimated Expiration: ⤷ Subscribe

Patent: 46094
Estimated Expiration: ⤷ Subscribe

Patent: 32926
Estimated Expiration: ⤷ Subscribe

Patent: 33898
Estimated Expiration: ⤷ Subscribe

Patent: 46980
Estimated Expiration: ⤷ Subscribe

Patent: 95723
Estimated Expiration: ⤷ Subscribe

Patent: 07700
Estimated Expiration: ⤷ Subscribe

Patent: 17511
Estimated Expiration: ⤷ Subscribe

Patent: 92140
Estimated Expiration: ⤷ Subscribe

Patent: 1109049
Patent: Compositions for respiratory delivery of active agents and associated methods and systems
Estimated Expiration: ⤷ Subscribe

Patent: 1109050
Patent: Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting &bgr;2 adrenergic receptor agonists and associated methods and systems
Estimated Expiration: ⤷ Subscribe

Patent: 1109051
Patent: Compositions, methods and systems for respiratory delivery of two or more active agents
Estimated Expiration: ⤷ Subscribe

Patent: 1642836
Patent: Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting [beta]2 adrenergic receptor agonists and associated methods and systems
Estimated Expiration: ⤷ Subscribe

Patent: 1700123
Patent: Compositions for respiratory delivery of active agents and associated methods and systems
Estimated Expiration: ⤷ Subscribe

Patent: 1808372
Patent: Compositions, methods and systems for respiratory delivery of two or more active agents
Estimated Expiration: ⤷ Subscribe

Patent: 1919730
Patent: Compositions for respiratory delivery of active agents and associated methods and systems
Estimated Expiration: ⤷ Subscribe

Patent: 1936174
Patent: Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting [beta]2 adrenergic receptor agonists and associated methods and systems
Estimated Expiration: ⤷ Subscribe

Patent: 2114642
Patent: Compositions, methods and systems for respiratory delivery of two or more active agents
Estimated Expiration: ⤷ Subscribe

Ukraine

Patent: 9529
Patent: КОМПОЗИЦІЇ ДЛЯ РЕСПІРАТОРНОЇ ДОСТАВКИ АКТИВНИХ АГЕНТІВ ТА ПОВ'ЯЗАНІ СПОСОБИ І СИСТЕМИ
Estimated Expiration: ⤷ Subscribe

Patent: 9530
Patent: КОМПОЗИЦІЇ, СПОСОБИ ТА СИСТЕМИ ДЛЯ ДОСТАВКИ РЕСПІРАТОРНИМ ШЛЯХОМ ДВОХ ЧИ БІЛЬШЕ АКТИВНИХ АГЕНТІВ
Estimated Expiration: ⤷ Subscribe

Patent: 9531
Patent: КОМПОЗИЦІЇ ДЛЯ ЛЕГЕНЕВОЇ ДОСТАВКИ МУСКАРИНОВИХ АНТАГОНІСТІВ ТРИВАЛОЇ ДІЇ ТА АГОНІСТІВ АДРЕНЕРГІЧНИХ РЕЦЕПТОРІВ B2 ТРИВАЛОЇ ДІЇ ТА ПОВ'ЯЗАНІ СПОСОБИ І СИСТЕМИ
Estimated Expiration: ⤷ Subscribe

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering bevespi aerosphere around the world.

Subscribe to access the full database, or Subscribe
Country	Patent Number	Title	Estimated Expiration
Hong Kong	1169027		⤷ Subscribe
World Intellectual Property Organization (WIPO)	2010138862		⤷ Subscribe
Taiwan	201109050	Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting &bgr;2 adrenergic receptor agonists and associated methods and systems	⤷ Subscribe
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for bevespi aerosphere

Subscribe to access the full database, or Subscribe
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2435025	132019000000087	Italy	⤷ Subscribe	PRODUCT NAME: UNA COMBINAZIONE DI GLICOPIRROLATO (INCLUSI SUOI SALI, ESTERI, ENANTIOMERI O ALTRI DERIVATI FARMACEUTICAMENTE ACCETTABILI) E FORMOTEROLO (INCLUSI SUOI SALI, ESTERI, ENANTIOMERI O ALTRI DERIVATI FARMACEUTICAMENTE ACCETTABILI)(BEVESPI AEROSPHERE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1339, 20181220
2435024	21C1020	France	⤷ Subscribe	PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI), GLYCOPYRROLATE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI) ET BUDESONIDE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI); REGISTRATION NO/DATE: EU/1/20/1498 20201210
2435024	CA 2021 00014	Denmark	⤷ Subscribe	PRODUCT NAME: KOMBINATION AF FORMOTEROL, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, SOLVATER ELLER ENANTIOMERE DERAF, GLYCOPYRROLAT, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, SOLVATER ELLER ENANTIOMERE DERAF, OG BUDESONID, HERUNDER...; REG. NO/DATE: EU/1/20/1498 20201210
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Bevespi aerosphere Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for BEVESPI AEROSPHERE

Introduction to BEVESPI AEROSPHERE

BEVESPI AEROSPHERE is a prescription medication developed by AstraZeneca, designed to treat chronic obstructive pulmonary disease (COPD) in adults. It is a combination of two COPD medicines: glycopyrrolate and formoterol fumarate, which work together to open airways and improve breathing[1].

Market Context: Respiratory Drug Market

The global respiratory drug market is experiencing significant growth, driven by the increasing prevalence of respiratory diseases such as COPD. The market was valued at USD 43,040 million in 2023 and is projected to reach USD 71,489.66 million by 2032, with a CAGR of 5.8% during the forecast period[3].

Competitive Landscape

In the COPD treatment market, BEVESPI AEROSPHERE faces stiff competition from other established drugs. One of its main competitors is Anoro Ellipta from GlaxoSmithKline (GSK), which has been on the market since December 2013. Despite being FDA-approved in April 2016, BEVESPI AEROSPHERE has struggled to gain significant market share compared to Anoro Ellipta[4].

Phase 3b AERISTO Trial

AstraZeneca conducted the Phase 3b AERISTO trial to compare BEVESPI AEROSPHERE with Anoro Ellipta. However, the trial results were mixed, with BEVESPI AEROSPHERE failing to demonstrate superiority over Anoro Ellipta in terms of peak and trough forced expiratory volume in one second (FEV1). Although it showed non-inferiority on peak FEV1, the overall performance was inconsistent with previous data[4][5].

Financial Performance

Sales Figures

The financial performance of BEVESPI AEROSPHERE has been modest compared to its competitors. In 2017, while Anoro Ellipta generated $440 million in sales, BEVESPI AEROSPHERE only managed $16 million. This significant disparity highlights the challenges BEVESPI AEROSPHERE faces in gaining market traction[4].

AstraZeneca's Respiratory Segment

AstraZeneca's overall respiratory segment has seen mixed results. In the first half of 2018, the company reported $2.4 billion in sales for its respiratory products, which was flat compared to the same period the previous year. This stability, however, does not reflect the specific performance of BEVESPI AEROSPHERE, which has struggled to make a significant impact[4].

Pricing and Accessibility

Starting June 1, 2024, AstraZeneca has introduced a pricing initiative where eligible patients can pay as little as $35 per month for BEVESPI AEROSPHERE. This move aims to improve accessibility and affordability, potentially boosting sales and market penetration[1].

Future Outlook

Despite the current challenges, AstraZeneca is continuing to invest in its respiratory pipeline. The company is developing a triple combination therapy, PT010, which has shown promising results in Phase 3 trials. This could potentially offer a more competitive edge in the COPD treatment market[4].

Market Trends

The respiratory drug market is trending towards the adoption of combination therapies and biologics, which offer improved efficacy and safety profiles. BEVESPI AEROSPHERE, as a combination therapy, aligns with this trend but needs to demonstrate superior clinical outcomes to gain market share[3].

Challenges and Opportunities

Clinical Performance

The inconsistent performance of BEVESPI AEROSPHERE in clinical trials, particularly the AERISTO trial, has been a significant setback. A full analysis is underway to understand these findings, which will be crucial for future development and marketing strategies[4][5].

Market Competition

The dominance of competitors like GSK's Anoro Ellipta and the upcoming triple combination therapies pose significant challenges. However, the growing demand for effective COPD treatments presents an opportunity for BEVESPI AEROSPHERE to carve out a niche if it can demonstrate superior clinical benefits and patient outcomes.

Key Takeaways

Market Growth: The global respiratory drug market is growing, driven by the increasing prevalence of respiratory diseases.
Competitive Landscape: BEVESPI AEROSPHERE faces strong competition from established drugs like Anoro Ellipta.
Clinical Trials: Mixed results from the AERISTO trial have impacted BEVESPI AEROSPHERE's market performance.
Financial Performance: Modest sales figures compared to competitors, with ongoing efforts to improve accessibility through pricing initiatives.
Future Outlook: Continued investment in the respiratory pipeline, including the development of triple combination therapies.

FAQs

Q: What is BEVESPI AEROSPHERE used for?

BEVESPI AEROSPHERE is a prescription medication used to treat chronic obstructive pulmonary disease (COPD) in adults, helping to open airways and improve breathing[1].

Q: How does BEVESPI AEROSPHERE compare to other COPD treatments?

BEVESPI AEROSPHERE has struggled to demonstrate superiority over competitors like GSK's Anoro Ellipta in clinical trials, although it has shown non-inferiority in some metrics[4].

Q: What are the common side effects of BEVESPI AEROSPHERE?

Common side effects of BEVESPI AEROSPHERE include urinary tract infections and cough[1].

Q: Is BEVESPI AEROSPHERE a rescue inhaler?

No, BEVESPI AEROSPHERE is not a rescue inhaler and is not used to treat sudden COPD symptoms. It is a maintenance treatment used twice daily[1].

Q: What are the pricing initiatives for BEVESPI AEROSPHERE?

Starting June 1, 2024, eligible patients can pay as little as $35 per month for BEVESPI AEROSPHERE, making it more accessible and affordable[1].

Sources

BEVESPI AEROSPHERE: BEVESPI AEROSPHERE® (glycopyrrolate/formoterol fumarate ...
AstraZeneca Financial Report: Full year and Q4 2022 results | AstraZeneca
Respiratory Drug Market Report: Respiratory Drug Market Size, Share & Growth Analysis | 2031
BioPharma Dive: AstraZeneca's COPD drug fails to beat out GSK rival - BioPharma Dive
AstraZeneca Update on AERISTO Trial: AstraZeneca provides update on AERISTO Phase IIIb trial for ...

More… ↓

⤷ Subscribe

Indicators of Generic Entry

AI Research Assistant

Questions you can ask:

Summary for bevespi aerosphere

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for bevespi aerosphere

Recent Clinical Trials for bevespi aerosphere

Pharmacology for bevespi aerosphere

When does loss-of-exclusivity occur for bevespi aerosphere?

Bevespi aerosphere Market Analysis and Financial Projection Experimental

Introduction to BEVESPI AEROSPHERE

Market Context: Respiratory Drug Market

Competitive Landscape

Phase 3b AERISTO Trial

Financial Performance

Sales Figures

AstraZeneca's Respiratory Segment

Pricing and Accessibility

Future Outlook

Market Trends

Challenges and Opportunities

Clinical Performance

Market Competition

Key Takeaways

FAQs

Q: What is BEVESPI AEROSPHERE used for?

Q: How does BEVESPI AEROSPHERE compare to other COPD treatments?

Q: What are the common side effects of BEVESPI AEROSPHERE?

Q: Is BEVESPI AEROSPHERE a rescue inhaler?

Q: What are the pricing initiatives for BEVESPI AEROSPHERE?

Sources

Make Better Decisions: Try a trial or see plans & pricing

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for bevespi aerosphere